Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis
Laura K. Cole, René L. Jacobs, Dennis E. Vance – 16 June 2010 – Tamoxifen is an anti‐estrogen drug widely used for the treatment of hormone‐sensitive breast cancer. Approximately 43% of breast cancer patients treated with tamoxifen develop hepatic steatosis. The mechanism or mechanisms by which tamoxifen may induce lipid accumulation in the liver are unclear. Mice were injected with tamoxifen or vehicle (sesame oil containing 1% benzyl alcohol) for 5 consecutive days. In comparison with the vehicle, tamoxifen increased hepatic triacylglycerol levels by 72%.